A phase 3, multicenter, randomized, open-label trial of Trastuzumab Deruxtecan in combination with Pembrolizumab versus platinum-based chemotherapy in combination with Pembrolizumab, as first-line therapy in participants with locally advanced unresectable or metastatic her2 overexpressing and PD-L1 TPS <50% non-squamous non-small cell lung cancer (DESTINY-Lung06)

Description

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.

Resources and Links

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT06899126 Opens a new window